{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T16:30:33Z","timestamp":1793118633711,"version":"4.5.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,7,2]],"date-time":"2021-07-02T00:00:00Z","timestamp":1625184000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,7,2]],"date-time":"2021-07-02T00:00:00Z","timestamp":1625184000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cardiovasc Disord"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Treatment of heart failure with reduced ejection fraction (HFrEF) has been revolutionized by angiotensin receptor\/neprilysin inhibitor (ARNI). ARNI has been shown to significantly reduce morbidity and mortality in a large, randomized controlled trial. However, real-world evaluation of ARNI with a diverse population is still limited.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>HFrEF patients receiving angiotensin receptor\/neprilysin inhibitor (ARNI) or standard HF treatment at a university hospital in Thailand were prospectively followed-up from January 2015 to December 2019. The primary outcome was a composite of all-cause mortality and heart failure hospitalization. Survival analysis and the Cox proportional hazard model were used to compare clinical outcomes between the two groups.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>During a follow-up period of 12\u00a0months, the primary outcome occurred in 10 patients in the ARNI group (11.5%) and 28 in the standard treatment group (28.0%) (hazard ratio 0.34; 95% CI: 0.15\u20130.80; <jats:italic>p<\/jats:italic>\u2009=\u20090.013). After adjustment for confounding factors, ARNI was significantly associated with a significant reduction in the primary outcome (HR 0.32, 95% CI: 0.13\u20130.82, <jats:italic>p<\/jats:italic>\u2009=\u20090.017). In addition, ARNI was also significantly associated with a decrease in the clinical signs and symptoms of HF, including dyspnea, orthopnea, and fatigue. Orthostatic hypotension was more frequently reported among the ARNI group than among the standard treatment group. The rates of target dose achievement were comparable between the two groups.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>In real-world practice, ARNI use was associated with a significant reduction in both clinical outcomes and symptom improvement, while orthostatic hypotension was more common in patients in the ARNI group than in patients in the standard treatment group.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12872-021-02145-9","type":"journal-article","created":{"date-parts":[[2021,7,2]],"date-time":"2021-07-02T12:02:40Z","timestamp":1625227360000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Real-world experience of angiotensin receptor\/neprilysin inhibitor (ARNI) usage in Thailand: a single-center, retrospective analysis"],"prefix":"10.1186","volume":"21","author":[{"given":"Wipharak","family":"Rattanavipanon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thanyaluck","family":"Sotananusak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fairus","family":"Yamaae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arisa","family":"Chandrsawang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pitchapa","family":"Kaewkan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Surakit","family":"Nathisuwan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teerapat","family":"Yingchoncharoen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,7,2]]},"reference":[{"issue":"9","key":"2145_CR1","doi-asserted-by":"publisher","first-page":"e139","DOI":"10.1161\/CIR.0000000000000757","volume":"141","author":"SS Virani","year":"2020","unstructured":"Virani SS, Alonso A, Benjamin EJ, Bittencourt MS, Callaway CW, Carson AP, et al. Heart Disease and Stroke Statistics-2020 Update: a report from the American Heart Association. Circulation. 2020;141(9):e139\u2013596.","journal-title":"Circulation"},{"issue":"1","key":"2145_CR2","doi-asserted-by":"publisher","first-page":"7","DOI":"10.15420\/cfr.2016:25:2","volume":"3","author":"G Savarese","year":"2017","unstructured":"Savarese G, Lund LH. Global public health burden of heart failure. Card Fail Rev. 2017;3(1):7\u201311.","journal-title":"Card Fail Rev"},{"key":"2145_CR3","doi-asserted-by":"publisher","unstructured":"Lippi G, Sanchis-Gomar F. Global epidemiology and future trends of heart failure. AME Med J. 2020. doi: https:\/\/doi.org\/10.21037\/amj.2020.03.03","DOI":"10.21037\/amj.2020.03.03"},{"key":"2145_CR4","doi-asserted-by":"crossref","unstructured":"Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2016;18(8):891\u2013975.","DOI":"10.1002\/ejhf.592"},{"issue":"6","key":"2145_CR5","doi-asserted-by":"publisher","first-page":"e137","DOI":"10.1161\/CIR.0000000000000509","volume":"136","author":"CW Yancy","year":"2017","unstructured":"Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Colvin MM, et al. 2017 ACC\/AHA\/HFSA Focused Update of the 2013 ACCF\/AHA Guideline for the Management of Heart Failure: a Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation. 2017;136(6):e137\u201361.","journal-title":"Circulation"},{"issue":"11","key":"2145_CR6","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1056\/NEJMoa1409077","volume":"371","author":"JJ McMurray","year":"2014","unstructured":"McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371(11):993\u20131004.","journal-title":"N Engl J Med"},{"issue":"2","key":"2145_CR7","doi-asserted-by":"publisher","first-page":"143","DOI":"10.11613\/BM.2013.018","volume":"23","author":"ML McHugh","year":"2013","unstructured":"McHugh ML. The chi-square test of independence. Biochem Med. 2013;23(2):143\u20139.","journal-title":"Biochem Med"},{"issue":"253","key":"2145_CR8","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1080\/01621459.1951.10500769","volume":"46","author":"FJ Massey","year":"1951","unstructured":"Massey FJ. The Kolmogorov-smirnov test for goodness of fit. J Am Stat Assoc. 1951;46(253):68\u201378.","journal-title":"J Am Stat Assoc"},{"key":"2145_CR9","doi-asserted-by":"crossref","unstructured":"Kalpi\u0107 D, Hlupi\u0107 N, Lovri\u0107 M. Student\u2019s t-tests. In: Lovric M, editor. International Encyclopedia of Statistical Science. Berlin, Heidelberg: Springer Berlin Heidelberg; 2011. p. 1559\u201363.","DOI":"10.1007\/978-3-642-04898-2_641"},{"key":"2145_CR10","doi-asserted-by":"crossref","unstructured":"Neuh\u00e4user M. Wilcoxon\u2013Mann\u2013Whitney Test. In: Lovric M, editor. International Encyclopedia of Statistical Science. Berlin: Springer; 2011. p. 1656\u20138.","DOI":"10.1007\/978-3-642-04898-2_615"},{"key":"2145_CR11","doi-asserted-by":"crossref","unstructured":"May WL. Kaplan-Meier Survival Analysis. In: Schwab M, editor. Encyclopedia of Cancer. Berlin: Springer; 2009. p. 1590\u20133.","DOI":"10.1007\/978-3-540-47648-1_3196"},{"key":"2145_CR12","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.ijcard.2021.01.061","volume":"331","author":"C Proudfoot","year":"2021","unstructured":"Proudfoot C, Studer R, Rajput T, Jindal R, Agrawal R, Corda S, et al. Real-world effectiveness and safety of sacubitril\/valsartan in heart failure: a systematic review. Int J Cardiol. 2021;331:164\u201371.","journal-title":"Int J Cardiol"},{"issue":"2","key":"2145_CR13","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1177\/1074248419872958","volume":"25","author":"FC Hsiao","year":"2020","unstructured":"Hsiao FC, Wang CL, Chang PC, Lu YY, Huang CY, Chu PH. Angiotensin receptor neprilysin inhibitor for patients with heart failure and reduced ejection fraction: real-world experience From Taiwan. J Cardiovasc Pharmacol Ther. 2020;25(2):152\u20137.","journal-title":"J Cardiovasc Pharmacol Ther"},{"issue":"3","key":"2145_CR14","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.jjcc.2019.08.005","volume":"75","author":"HY Chang","year":"2020","unstructured":"Chang HY, Chen KC, Fong MC, Feng AN, Fu HN, Huang KC, et al. Recovery of left ventricular dysfunction after sacubitril\/valsartan: predictors and management. J Cardiol. 2020;75(3):233\u201341.","journal-title":"J Cardiol"},{"issue":"5","key":"2145_CR15","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1016\/j.hlc.2020.08.014","volume":"30","author":"BLK Chng","year":"2021","unstructured":"Chng BLK, Hon JS, Chan H, Zheng Y, Gao F, Teo LYL, et al. Safety and tolerability of sacubitril\/valsartan initiation in inpatient versus outpatient setting: a retrospective real world study. Heart Lung Circ. 2021;30(5):674\u201382.","journal-title":"Heart Lung Circ"},{"issue":"4","key":"2145_CR16","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1002\/ehf2.12452","volume":"6","author":"B Atallah","year":"2019","unstructured":"Atallah B, Sadik ZG, Hisham M, Kalagieh O, Hamour I, Gabra G, et al. A per-protocol initiation of sacubitril\/valsartan in an advanced heart failure disease management programme in the Middle East Gulf Region. ESC Heart Fail. 2019;6(4):758\u201363.","journal-title":"ESC Heart Fail"},{"issue":"4","key":"2145_CR17","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/j.jjcc.2019.03.010","volume":"74","author":"HY Chang","year":"2019","unstructured":"Chang HY, Feng AN, Fong MC, Hsueh CW, Lai WT, Huang KC, et al. Sacubitril\/valsartan in heart failure with reduced ejection fraction patients: real world experience on advanced chronic kidney disease, hypotension, and dose escalation. J Cardiol. 2019;74(4):372\u201380.","journal-title":"J Cardiol"},{"key":"2145_CR18","doi-asserted-by":"crossref","unstructured":"Chang PC, Wang CL, Hsiao FC, Wen MS, Huang CY, Chou CC, et al. Sacubitril\/valsartan vs. angiotensin receptor inhibition in heart failure: a real-world study in Taiwan. ESC Heart Fail. 2020;7(5):3003\u201312.","DOI":"10.1002\/ehf2.12924"},{"issue":"1","key":"2145_CR19","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1038\/s41572-019-0084-1","volume":"5","author":"H-P Schultheiss","year":"2019","unstructured":"Schultheiss H-P, Fairweather D, Caforio ALP, Escher F, Hershberger RE, Lipshultz SE, et al. Dilated cardiomyopathy. Nat Rev Dis. 2019;5(1):32. https:\/\/doi.org\/10.1038\/s41572-019-0084-1.","journal-title":"Nat Rev Dis"},{"issue":"4","key":"2145_CR20","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.hfc.2008.03.008","volume":"4","author":"A Ahmed","year":"2008","unstructured":"Ahmed A, Campbell RC. Epidemiology of chronic kidney disease in heart failure. Heart Fail Clin. 2008;4(4):387\u201399.","journal-title":"Heart Fail Clin"},{"issue":"13","key":"2145_CR21","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1161\/CIRCULATIONAHA.120.047643","volume":"142","author":"FR Mc Causland","year":"2020","unstructured":"Mc Causland FR, Lefkowitz MP, Claggett B, Anavekar NS, Senni M, Gori M, et al. Angiotensin-neprilysin inhibition and renal outcomes in heart failure with preserved ejection fraction. Circulation. 2020;142(13):1236\u201345.","journal-title":"Circulation"},{"issue":"8","key":"2145_CR22","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1007\/s11739-019-02111-6","volume":"14","author":"F Spannella","year":"2019","unstructured":"Spannella F, Marini M, Giulietti F, Rosettani G, Francioni M, Perna GP, et al. Renal effects of Sacubitril\/Valsartan in heart failure with reduced ejection fraction: a real life 1-year follow-up study. Intern Emerg Med. 2019;14(8):1287\u201397.","journal-title":"Intern Emerg Med"}],"container-title":["BMC Cardiovascular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-021-02145-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12872-021-02145-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-021-02145-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,2]],"date-time":"2021-07-02T12:04:55Z","timestamp":1625227495000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccardiovascdisord.biomedcentral.com\/articles\/10.1186\/s12872-021-02145-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,2]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["2145"],"URL":"https:\/\/doi.org\/10.1186\/s12872-021-02145-9","relation":{},"ISSN":["1471-2261"],"issn-type":[{"value":"1471-2261","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,2]]},"assertion":[{"value":"24 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was approved by the Committee for Research, Faculty of Medicine Ramathibodi Hospital Mahidol University (MURA No. 2019\/1263) in 2019. Written informed consent was waived by the ethics committee (the Committee for Research, Faculty of Medicine Ramathibodi Hospital Mahidol University) because of the data retrospectively obtained from electronic medical records. This study complied with the principles of the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"324"}}